SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 7

Can routine hemogram parameters be used asinflammatory biomarker in chronic obstructive pulmonarydisease exacerbations?

Ayperi ÖZTÜRK
Tuğba ÇİÇEK
Pages
1321–1325
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Subjects were grouped according to NLR cut-off point determined by the ROC curve (NLR

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Confirming the diagnosis and identifying the etiology are critical for the management of chronic obstructive pulmonary disease (COPD) exacerbation.
📊
Key Findings & Data:The aim of this study was to investigate the association between procalcitonin, CRP, hemogram parameters and ratios, and the efficacy of new hematological ratios in differential diagnosis in subjects with COPD exacerbation.Materials and Methods: Subjects admitted to our outpatient clinic with the diagnosis of COPD were retrospectively analyzed and divided into 2 groups: those with acute exacerbation (n=52) and those are stable (n=64).
💡
Conclusion & Impact:Subjects were grouped according to NLR cut-off point determined by the ROC curve (NLR
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Confirming the diagnosis and identifying the etiology are critical for the management of chronic obstructive pulmonary disease (COPD) exacerbation. There is limited use of hemogram and C-reactive protein (CRP) in distinguishing infectious or non-infectious in exacerbations. However, procalcitonin is more precious in making this distinction, although it is less accessible and more expensive. The aim of this study was to investigate the association between procalcitonin, CRP, hemogram parameters and ratios, and the efficacy of new hematological ratios in differential diagnosis in subjects with COPD exacerbation.Materials and Methods: Subjects admitted to our outpatient clinic with the diagnosis of COPD were retrospectively analyzed and divided into 2 groups: those with acute exacerbation (n=52) and those are stable (n=64). Neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR) and platelet-lymphocyte ratio (PLR) were calculated for both groups. Subjects were grouped according to NLR cut-off point determined by the ROC curve (NLR

🔖

Cite This Article

ÖZTÜRK, A., ÇİÇEK, T. (2022). Can routine hemogram parameters be used asinflammatory biomarker in chronic obstructive pulmonarydisease exacerbations?. Annals of Medical Research, Cilt: 28 - Sayı: 7, 1321–1325. https://ajindex.com/articles/445798

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017;195:557-82
  2. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103
  3. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what? Clin Respir J 2012;6:208-14
  4. Sykes A, Mallia P, Johnston SL. Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:642-6
  5. Vestbo J. Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2006;3:252-6
  6. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426-35
  7. Karzai W, Oberhoffer M, Meier-Hellmann A, et al. Procalcitonin--a new indicator of the systemic response to severe infections. Infection 1997;25:329- 34
  8. Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med 2016;31:891-8
  9. Kurtipek E, Bekci TT, Kesli R, et al. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. J Pak Med Assoc 2015;65:1283-7
  10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196- 204
  11. Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013;345:190-4
  12. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74
  13. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483
  14. Meisner M. Procalcitonin (PCT)-a new, innovative infection parameter. Biochemical and Clinical Aspects. 3. revised and expanded edition. New York: Thieme Stuttgart; 2000
  15. Chang C, Yao WZ, Chen YH, et al. [The changes